NASDAQ:BPMCBlueprint Medicines Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Blueprint Medicines Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $75.32 +0.87 (+1.17 %) (As of 08/10/2020 04:00 PM ET) Add Compare Share Today's Range$74.23Now: $75.32▼$76.1850-Day Range$73.18MA: $77.03▼$80.1052-Week Range$43.29Now: $75.32▼$91.25Volume215,543 shsAverage Volume728,200 shsMarket Capitalization$4.16 billionP/E RatioN/ADividend YieldN/ABeta1.03 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, an inhibitor targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingBlueprint Medicines has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $98.50, Blueprint Medicines has a potential upside of 30.8% from its current price of $75.32.Amount of Analyst CoverageBlueprint Medicines has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesBlueprint Medicines has received 446 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBlueprint Medicines has received 302 “underperform” votes. (Add your “underperform” vote.)Community SentimentBlueprint Medicines has received 59.63% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote “Outperform” if you believe BPMC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBlueprint Medicines does not currently pay a dividend.Dividend GrowthBlueprint Medicines does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,001,908.00 in company stock.Percentage Held by InsidersOnly 3.81% of the stock of Blueprint Medicines is held by insiders.Percentage Held by Institutions97.96% of the stock of Blueprint Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Blueprint Medicines are expected to decrease in the coming year, from $1.43 to ($6.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Blueprint Medicines is -9.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Blueprint Medicines is -9.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioBlueprint Medicines has a PEG Ratio of 1.53. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBlueprint Medicines has a P/B Ratio of 7.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.69 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BPMC Previous Symbol CUSIPN/A CIK1597264 Webwww.blueprintmedicines.com Phone617-374-7580Debt Debt-to-Equity Ratio0.15 Current Ratio5.41 Quick Ratio5.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio52.67 P/E Growth1.53 Sales & Book Value Annual Sales$66.51 million Price / Sales62.59 Cash FlowN/A Price / Cash FlowN/A Book Value$9.44 per share Price / Book7.98Profitability EPS (Most Recent Fiscal Year)($7.27) Net Income$-347,690,000.00 Net Margins-525.44% Return on Equity-70.39% Return on Assets-49.74%Miscellaneous Employees217 Outstanding Shares55,272,000Market Cap$4.16 billion Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $75.32 +0.87 (+1.17 %) (As of 08/10/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BPMC News and Ratings via Email Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions How has Blueprint Medicines' stock been impacted by COVID-19 (Coronavirus)? Blueprint Medicines' stock was trading at $52.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BPMC stock has increased by 43.7% and is now trading at $75.32. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Blueprint Medicines? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Blueprint Medicines. When is Blueprint Medicines' next earnings date? Blueprint Medicines is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Blueprint Medicines. How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Corp (NASDAQ:BPMC) released its earnings results on Thursday, July, 30th. The biotechnology company reported ($2.28) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.08) by $0.20. The biotechnology company had revenue of $8.34 million for the quarter, compared to analysts' expectations of $7.56 million. Blueprint Medicines had a negative net margin of 525.44% and a negative return on equity of 70.39%. View Blueprint Medicines' earnings history. What price target have analysts set for BPMC? 13 brokers have issued 1 year price targets for Blueprint Medicines' shares. Their forecasts range from $59.00 to $122.00. On average, they anticipate Blueprint Medicines' share price to reach $98.50 in the next year. This suggests a possible upside of 30.8% from the stock's current price. View analysts' price targets for Blueprint Medicines. Has Blueprint Medicines been receiving favorable news coverage? News stories about BPMC stock have trended somewhat negative on Monday, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Blueprint Medicines earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Blueprint Medicines. Are investors shorting Blueprint Medicines? Blueprint Medicines saw a increase in short interest in January. As of January 15th, there was short interest totaling 3,690,000 shares, an increase of 17.9% from the December 31st total of 3,130,000 shares. Based on an average daily volume of 654,000 shares, the days-to-cover ratio is currently 5.6 days. View Blueprint Medicines' Short Interest. Who are some of Blueprint Medicines' key competitors? Some companies that are related to Blueprint Medicines include Horizon Therapeutics (HZNP), Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), Sarepta Therapeutics (SRPT), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ) and Emergent Biosolutions (EBS). View all competitors. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), Micron Technology (MU), AbbVie (ABBV), Crispr Therapeutics (CRSP), Amarin (AMRN), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Nektar Therapeutics (NKTR), Alibaba Group (BABA) and Gilead Sciences (GILD). Who are Blueprint Medicines' key executives? Blueprint Medicines' management team includes the following people: Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 48)Mr. Alexis A. Borisy, Co-Founder & Director (Age 47)Mr. Michael Landsittel, Chief Financial Officer (Age 47)Ms. Kathryn Haviland, Chief Operating Officer (Age 43)Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 56) When did Blueprint Medicines IPO? (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Blueprint Medicines' stock symbol? Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC." Who are Blueprint Medicines' major shareholders? Blueprint Medicines' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Viking Global Investors LP (2.95%), Candriam Luxembourg S.C.A. (1.62%), TimesSquare Capital Management LLC (1.39%), Victory Capital Management Inc. (1.02%), Emerald Advisers LLC (0.73%) and Emerald Mutual Fund Advisers Trust (0.66%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Debra Durso-Bumpus, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View institutional ownership trends for Blueprint Medicines. Which institutional investors are selling Blueprint Medicines stock? BPMC stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Peregrine Capital Management LLC, Trexquant Investment LP, Emerald Advisers LLC, Veracity Capital LLC, Russell Investments Group Ltd., Emerald Mutual Fund Advisers Trust, and Oak Ridge Investments LLC. Company insiders that have sold Blueprint Medicines company stock in the last year include Anthony L Boral, Ariel Hurley, Debra Durso-Bumpus, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch, and Nicholas Lydon. View insider buying and selling activity for Blueprint Medicines. Which institutional investors are buying Blueprint Medicines stock? BPMC stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Alps Advisors Inc., Viking Global Investors LP, Swiss National Bank, First Trust Advisors LP, Envestnet Asset Management Inc., AE Wealth Management LLC, and New York State Common Retirement Fund. View insider buying and selling activity for Blueprint Medicines. How do I buy shares of Blueprint Medicines? Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Blueprint Medicines' stock price today? One share of BPMC stock can currently be purchased for approximately $75.32. How big of a company is Blueprint Medicines? Blueprint Medicines has a market capitalization of $4.16 billion and generates $66.51 million in revenue each year. The biotechnology company earns $-347,690,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe. What is Blueprint Medicines' official website? The official website for Blueprint Medicines is www.blueprintmedicines.com. How can I contact Blueprint Medicines? Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected] This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
